• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 30, 2024
Data Byte

Nine PDUFA dates on FDA’s agenda in September

Decision on Zevra’s arimoclomol follows positive AdCom vote
Read More
BioCentury | Jan 24, 2024
Data Byte

Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024

A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
Read More
BioCentury | Apr 25, 2022
Data Byte

Mechanistic diversity in the pipeline for fragile X syndrome

The fragile X pipeline comprises as many drugs targets as drug candidates
Read More
BioCentury | Mar 4, 2022
Distillery Therapeutics

Targeting GABA signals for cancer checkpoint inhibitor resistance

Read More
BioCentury | Aug 13, 2021
Product Development

Aug. 12 Quick Takes: another hold for Aprea’s eprenetapopt 

Plus Vyne, AlzeCure and Jazz 
Read More
BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

Kronos raises $250M in NASDAQ IPOLook for shares of Kronos Bio Inc. (NASDAQ:KRON) to begin trading on Friday after the company raised $250 million in an IPO. The listing completes a busy few months
Read More
BioCentury | Sep 25, 2020
Emerging Company Profile

XWPharma: timing therapy to biological rhythm

XWPharma to use $40M series C to advance two lead neurology programs
Read More
BioCentury | Jul 24, 2020
Product Development

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

Read More
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

Read More
BioCentury | Apr 5, 2019
Clinical News

Jazz planning NDA for narcolepsy therapy JZP-258

Read More
Items per page:
1 - 10 of 103
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa